Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Hepatology International · 2025
DOI: 10.1007/s12072-024-10764-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hepatology International, 2025. Verfasst von Zhili Tan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Interferon-alpha, Polyethylene Glycols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Pudong New Area Health Commission.
Abstract (Originalsprache)
Background and Aims Chronic hepatitis B (CHB) is a major global health concern. This study aims to investigate the factors influencing hepatitis B surface antigen (HBsAg) clearance in CHB patients treated with pegylated interferon α-2b (Peg-IFNα-2b) for 48 weeks and to establish a predictive model.
Methods
This analysis is based on the “OASIS” project, a prospective real-world multicenter study in China. We included CHB patients who completed 48 weeks of Peg-IFNα-2b treatment. Patients were randomly assigned to a training set and a validation set in a ratio of approximately 4:1 by spss 26.0, and were divided into clearance and non-clearance groups based on HBsAg status at 48 weeks. Clinical data were analyzed using SPSS 26.0, employing chi-square tests for categorical data and Mann–Whitney U tests for continuous variables. Significant factors ( p < 0.05) were incorporated into a binary logistic regression model to identify independent predictors of HBsAg clearance. The predictive model’s performance was evaluated using ROC curve analysis.
Results
We included 868 subjects, divided into the clearance group (187 cases) and the non-clearance group (681 cases). They were randomly assigned to a training set (702 cases) and a validation set (166 cases). Key predictors included female gender (OR = 1.879), lower baseline HBsAg levels (OR = 0.371), and cirrhosis (OR = 0.438). The final predictive model was: Logit(P) = 0.92 + Gender (Female) * 0.66 - HBsAg (log) * 0.96 - Cirrhosis * 0.88. ROC analysis showed an AUC of 0.80 for the training set and 0.82 for the validation set, indicating good predictive performance.
Conclusion
Gender, baseline HBsAg levels, and cirrhosis are significant predictors of HBsAg clearance in CHB patients after 48 weeks of Peg-IFNα-2b therapy. The developed predictive model demonstrates high accuracy and potential clinical utility .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan Univ…
- Department of Infectious Diseases, Yanan University Affiliated Hospital, Yan'an, Shaanxi, China.
- Department of Infectious Disease and Hepatic Disease, Henan Provincial People's Hospital, Henan, China.
- Department of Infectious Disease and Hepatic Disease, First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
- Deparment of Hepatology, The Third People's Hospital of Taiyuan, Taiyuan, China. taiyuanguoying001@163.com.
Förderung
- Shanghai Pudong New Area Health Commission
Zitieren
APA
Tan, Z., Kong, N., Zhang, Q., Gao, X., Shang, J., Geng, J., You, R., Wang, T., Guo, Y., Wu, X., Zhang, W., Qu, L., & Zhang, F. (2025). Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks. Hepatology International. https://doi.org/10.1007/s12072-024-10764-5
Vancouver
Tan Z, Kong N, Zhang Q, Gao X, Shang J, Geng J, et al. Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks. Hepatology International. 2025. doi:10.1007/s12072-024-10764-5
BibTeX
@article{Tan2025,
author = {Tan, Zhili and Kong, Nan and Zhang, Qiran and Gao, Xiaohong and Shang, Jia and Geng, Jiawei and You, Ruirui and Wang, Tao and Guo, Ying and Wu, Xiaoping and Zhang, Wenhong and Qu, Lihong and Zhang, Fengdi},
title = {Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks},
journal = {Hepatology International},
year = {2025},
doi = {10.1007/s12072-024-10764-5}
}
EUVIMED